An mRNA flu vaccine is a type of immunization that uses messenger RNA technology to instruct your cells to produce influenza antigens, effectively training your immune system to recognize and fight the virus. Unlike traditional flu shots, which are often egg-based and contain inactivated viral proteins, mRNA vaccines provide your body with a genetic blueprint to create those proteins internally. The FDA recently approved mFLUSIVA, manufactured by Moderna, as the first mRNA-based influenza vaccine available for adults aged 50 and older. This approval marks a significant shift in how seasonal influenza is managed, particularly for older populations who are at a higher risk of severe complications from the virus.
According to data from the FDA, clinical trials involving more than 40,000 participants aged 50 and older demonstrated that the mRNA vaccine was 26% more effective at preventing laboratory-confirmed influenza compared to conventional licensed standard-dose vaccines. This jump in efficacy is notable because traditional flu vaccine effectiveness can fluctuate annually depending on how well the vaccine strains match the circulating virus. By leveraging the flexibility of mRNA technology, manufacturers aim to adjust and produce updated vaccines more quickly to keep pace with evolving viral strains.
Traditional flu vaccines have relied on decades-old manufacturing processes, often involving the growth of viruses in chicken eggs. This process is time-consuming and can lead to mutations during production that may reduce the vaccine's overall effectiveness. In contrast, mRNA technology bypasses the need for large-scale viral cultivation. Instead, the vaccine delivers a synthetic strand of mRNA encapsulated in a lipid nanoparticle. Once injected, your cells translate this genetic code into harmless flu proteins. Your immune system detects these proteins, identifies them as foreign, and produces the necessary antibodies and T-cells to protect you from future exposure.
This approach offers several potential advantages. First, the speed of production is significantly faster, as the manufacturing process is synthetic rather than biological. Second, the precision of the mRNA sequence allows researchers to target specific parts of the virus with greater accuracy. As noted by the Centers for Disease Control and Prevention (CDC), while conventional vaccines remain the gold standard for public health, the introduction of mRNA platforms provides a more modern tool to combat respiratory illnesses that frequently mutate.
Keep exploring
More from GroundworkThe FDA granted full approval for the use of mFLUSIVA in adults aged 50 to 64 following extensive phase 3 clinical data. For individuals aged 65 and older, the FDA granted accelerated approval. This designation is based on findings from a clinical trial of approximately 3,000 older adults, which indicated that the mRNA vaccine generated stronger antibody responses compared to existing high-dose flu vaccines.
Because this is an accelerated approval, Moderna has committed to conducting additional post-market studies to further confirm the clinical benefits and safety profile in the 65-plus demographic. It is important to note that this vaccine is currently undergoing regulatory review in several international jurisdictions, including Europe, Canada, and Australia. While the technology is new for the flu, its application follows the widespread use of mRNA platforms during the COVID-19 pandemic, which provided a massive dataset regarding the safety and reactogenicity of this vaccine class.
When deciding on your annual flu shot, it is helpful to understand the landscape of available options. Traditional flu vaccines manufactured by companies such as Sanofi, GSK, CSL Seqirus, and AstraZeneca will continue to be widely available. These vaccines have a long track record of safety and are proven to reduce the severity of flu symptoms, hospitalizations, and deaths.
If you are 50 or older, you now have a choice between the conventional egg-based or cell-based shots and the new mRNA-based option. While mRNA technology showed a 26% higher efficacy in the initial trials compared to standard-dose vaccines, clinical efficacy can vary based on the specific flu season and circulating strains. The decision to switch to an mRNA platform should be discussed with your primary care provider, especially if you have a history of severe reactions to vaccines or specific underlying health conditions.
- Consult your healthcare provider: Ask your doctor if the mRNA flu vaccine is appropriate for your specific health profile, especially if you are over 65.
- Verify availability: Check with your local pharmacy or primary care clinic to see if they are stocking the mRNA flu vaccine versus traditional options.
- Monitor for symptoms: Regardless of the vaccine type, stay vigilant for influenza symptoms and consult a doctor early if you feel unwell, as antivirals can be effective if started within 48 hours of symptom onset.
- Stay updated: Follow official guidance from the CDC regarding the 2026–2027 influenza season to understand the predicted severity of the virus in your region.
While the introduction of mRNA technology represents a technological leap, public health remains focused on the primary goal: reducing the burden of respiratory disease. Whether you choose the new mRNA vaccine or a traditional flu shot, completing your immunization remains the most reliable way to lower your risk of severe illness during the winter months.
